|
2025
|
Invention
|
1-h-pyrrolo[2,3-c]pyridine compounds.
Compounds having the structure of Formula (I):
Compounds... |
|
2024
|
Invention
|
Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on b... |
|
|
Invention
|
Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yljimidazo[1,5-a... |
|
|
Invention
|
1-h-pyrrolo[2,3-c]pyridine compounds acting against cancer via agonism of menin. Compounds having... |
|
2023
|
Invention
|
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment.
In certai... |
|
|
Invention
|
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor.
Therapeutic combinations of a ... |
|
|
Invention
|
Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-... |
|
|
Invention
|
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a btk inhib... |
|
|
Invention
|
Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors.
T... |
|
2022
|
Invention
|
Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(... |
|
2021
|
Invention
|
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 ... |
|
|
Invention
|
Acalabrutinib maleate dosage forms.
The present disclosure relates, in general, to: (a) solid ph... |
|
|
Invention
|
Acalabrutinib maleate dosage forms. The present disclosure relates, in general, to: (a) solid pha... |
|
2020
|
Invention
|
Imidazopyrazine inhibitors of bruton's tyrosine kinase. In some embodiments, the invention relate... |
|
2019
|
Invention
|
Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a... |
|
|
Invention
|
Therapeutic combinations of an antifolate and a btk inhibitor.
Therapeutic combinations of an an... |
|
|
Invention
|
Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase. In some embodiments, the inv... |
|
|
Invention
|
Therapeutic combination of a pi3k inhibitor and a btk inhibitor.
In some embodiments, the invent... |
|
|
Invention
|
Therapeutic combinations of a mek inhibitor and a btk inhibitor. Therapeutic combinations of a ME... |
|
|
Invention
|
Therapeutic combinations of an irak4 inhibitor and a btk inhibitor.
Therapeutic combinations of ... |
|
|
Invention
|
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibito... |
|
|
Invention
|
Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinas... |
|
2018
|
Invention
|
Therapeutic combinations of a proteasome inhibitor and a btk inhibitor.
Therapeutic combinations... |
|
|
Invention
|
Pharmaceutical composition comprising a crystal form of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolid... |
|
|
Invention
|
Methods of using btk inhibitors to treat dermatoses.
In certain embodiments, the invention inclu... |
|
|
Invention
|
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a cdk4/6... |
|
|
Invention
|
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor.
Therapeu... |
|
|
Invention
|
Compositions and methods for the assessment of drug target occupancy for bruton's tyrosine kinase... |
|
2017
|
Invention
|
Solid forms of imidazopyrazine compounds. In some embodiments, the invention relates to crystalli... |
|
|
Invention
|
Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors. Th... |
|
|
Invention
|
Pharmaceutical composition comprising a crystal form of (s)-4-(8-amino-3-(1-(but-2-ynoyl) pyrroli... |
|
2016
|
Invention
|
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an o... |
|
|
Invention
|
Therapeutic combinations of a mek inhibitor and a btk inhibitor.
Therapeutic combinations of a M... |
